Stephen Liu/LinkedIn
Apr 21, 2025, 10:17
Stephen Liu: PET surveillance in NSCLC after definitive therapy
Stephen Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, posted on X:
“PET surveillance in NSCLC after definitive therapy.
SUPE_R trial randomized 750 patients to PET/CT or CT alone.
PET increased detection of recurrence, but no difference in those treated with curative intent (48%); no difference in survival (HR 0.97).”
“Surveillance with [18F]FDG PET/CT of stage I-III lung cancer patients after completion of curative treatment (SUPE_R): a randomized controlled trial.”
Authors: Kasper Foged Guldbrandsen et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 21, 2025, 19:12
Apr 21, 2025, 18:19
Apr 21, 2025, 18:00
Apr 21, 2025, 17:40
Apr 21, 2025, 17:35
Apr 21, 2025, 17:29
Apr 21, 2025, 17:21
Apr 21, 2025, 17:00
Apr 21, 2025, 16:59